Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results

Biller, Beverly MK; Gilis-Januszewska, Aleksandra; Doknic, Mirjana; Pico, Antonio; Fleseriu, Maria

Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/39025

Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results

Ver/Abrir:
FORESIGTH.pdf

844,43 kB
Adobe PDF
Compartir:

Título :
Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results

Autor :
Biller, Beverly MK
Gilis-Januszewska, Aleksandra
Doknic, Mirjana
Pico, Antonio
Fleseriu, Maria

Editor :
Oxford University Press

Departamento:
Departamentos de la UMH::Medicina Clínica

Fecha de publicación:
2025

URI :
https://hdl.handle.net/11000/39025

Resumen :
Adult growth hormone (GH) deficiency (GHD) is characterized by metabolic abnormalities caused by insufficient GH production. Lonapegsomatropin, a prodrug administered once weekly, was designed to provide sustained release of unmodified somatropin to reduce the burden of daily somatropin injections.

Palabras clave/Materias:
Growth hormone
Growth hormone deficiency
Long-acting growth hormone
Adult growth hormone deficiency

Área de conocimiento :
CDU: Ciencias aplicadas: Medicina

Tipo de documento :
info:eu-repo/semantics/article

Derechos de acceso:
info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 Internacional

DOI :
https://doi.org/10.1210/clinem/dgaf680

Publicado en:
The Journal of Clinical Endocrinology & Metabolism 2025

Aparece en las colecciones:
Artículos Medicina Clínica

Mostrar el registro Dublin Core completo del ítem Ver estadísticas

La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.